Medicare will cover GLP-1s for weight loss starting July 2026
A new temporary program, the Medicare GLP-1 Bridge, lets some people with Medicare get GLP-1 medications for weight management at a flat $50 monthly copay starting July 1, 2026. Here is who qualifies and what it covers.
A first for Medicare
Starting July 1, 2026, Medicare will help pay for GLP-1 medications used specifically for weight management for the first time. It is happening through a new temporary program called the Medicare GLP-1 Bridge, run by the Centers for Medicare and Medicaid Services (CMS).
This is a genuinely new development. By law, Medicare has long been barred from covering medications used for weight loss. The Bridge gets around that through a time-limited demonstration project, which CMS is allowed to run to test new coverage and payment approaches. It is part of a broader CMS effort called the BALANCE Model.
The basics: cost and timeline
Eligible beneficiaries pay a flat $50 per month for a covered GLP-1, and the Part D deductible does not apply. The program starts July 1, 2026, and is scheduled to run through December 31, 2027. It is temporary, not a permanent benefit. Two details are worth knowing up front: the $50 copay does not count toward your true out-of-pocket spending, and there is no extra low-income subsidy applied to it.
Who qualifies
To be eligible, you first need to be enrolled in a Medicare Part D prescription drug plan, or a Medicare Advantage plan that includes drug coverage. The medication also has to be prescribed for chronic weight management, not for diabetes. Beyond that, eligibility is based on body mass index (BMI) and health conditions. You may qualify if you have a BMI of 35 or higher; a BMI of 30 or higher along with heart failure, uncontrolled high blood pressure, or kidney disease; or a BMI of 27 or higher (age 18 and up) with prediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease.
Which medications are covered
The program covers a specific list of GLP-1 products: Wegovy (both the injectable and the oral form), the Zepbound KwikPen, and Foundayo, a newer oral GLP-1 pill from Eli Lilly. The single-dose vial and single-dose pen versions of Zepbound are not included.
What this does not change
This is a demonstration with an end date, not a new permanent Medicare benefit. It does not cover everyone on Medicare, and it does not change the rules for diabetes prescriptions, which are handled separately. If you think you might be eligible, talk with your prescribing clinician about whether a GLP-1 is appropriate for you, and check the specifics with your Part D plan. CMS has set up a dedicated page at Medicare.gov/glp1bridge where people with Medicare can learn more.
How Titra helps
If the Bridge brings you onto a GLP-1 for the first time, the early weeks are where a companion app earns its place. Titra tracks your doses, side effects, protein, and weight in one record, shows you what is expected as you start, and turns weeks of logs into a clear summary you can bring to your next visit. This article is for general information and is not medical advice. Eligibility and costs depend on your individual Medicare plan and health status.